Priority And Standard Review Times Increasingly Similar As Application Totals Diverge
Standard NMEs and BLAs decrease along with their review times, as more sponsors use priority pathway.
You may also be interested in...
US FDA’s priority review voucher fee will decrease again in FY 2022 as the cost of a priority assessment continues to trend closer to the cost of a standard assessment.
Program growth beyond supplements will be determined after the agency gains experience with STAR program, PhRMA executive tells the Pink Sheet.
The agency reissued the user fee notice, saying fewer dollars were needed for new staff.